SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome
SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status
Viking Therapeutics stock surges as Phase 3 trials progress for its GLP-1 obesity drug, with analysts seeing major upside potential
Conference call scheduled for 4:30 p.m. ET today
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735
Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern TimeÂ
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ClearPoint Neuro (CLPT – Research Report), BioLife Solutions (BLFS – Research Report) and Viking Therapeutics...